RxDoctor Payments Data

Aaron Shupp, MD

Family Medicine · Pueblo, CONPI 1194164806

Payments from drug & device makers

$7,517in general payments, 2019–2025

Across 420 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$711
  • AstraZeneca$642
  • Amgen$490
  • Pfizer$435
  • Bayer$414
  • plus $4K from 47 others

What the payments were for

  • Consulting fees$230%
  • Food & beverage$7,46099%
  • Education$70%
  • Other$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,517 in reported general payments places this provider in the 95th percentile of 2,079 family medicine providers in Colorado.

See all family medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$34,254
Medicare patients
90
Services billed
1,625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala13$60,003
EliquisApixaban40$49,740
JardianceEmpagliflozin28$43,491
MyrbetriqMirabegron50$40,544
OzempicSemaglutide19$36,870
TrulicityDulaglutide13$35,883
MounjaroTirzepatide20$34,167
FarxigaDapagliflozin Propanediol19$24,674
XareltoRivaroxaban21$20,936
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$12,633
Advair HfaFluticasone Propion/Salmeterol17$7,421
Omeprazole103$3,165
Atorvastatin Calcium292$2,701
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl16$2,619
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen50$1,985

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$711$70,05033 claims
GileadBiktarvy$57$60,00313 claims
PfizerEliquis$435$49,74040 claims
Boehringer IngelheimJardiance$308$43,49128 claims
Astellas Pharma US IncMyrbetriq$162$40,54450 claims
Novo NordiskOzempic$290$36,87019 claims
AstraZenecaFarxiga$642$24,67419 claims
Johnson & JohnsonXarelto$128$20,93621 claims
GSKTrelegy Ellipta$301$12,63311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,079 family medicine providers in Colorado.

Other family medicine in Pueblo

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →